Vanishing white matter (VWM) is a fatal, stress-sensitive leukodystrophy that mainly affects children and is currently without treatment. VWM is caused by recessive mutations in eukaryotic initiation factor 2B (eIF2B) that is crucial for initiation of mRNA translation and its regulation under stress conditions. Mice with bi-allelic missense mutations in eIF2B recapitulate human VWM. VWM pathomechanisms are unclear. Using polysomal profiling to screen for mRNAs with altered translation we observed most prominent changes in expression of integrated stress response (ISR) mRNAs in brains of mutant compared to wild-type mice; expression levels correlated with disease severity. We substantiated these findings in VWM patients' brains. ISRIB, an ISR inhibitor, normalized expression of mRNA markers, ameliorated white matter pathology and improved motor skills in VWM mice, thus showing that the ISR is central in VWM pathomechanisms and a viable target for therapy.
Introduction
Vanishing white matter (VWM) is a leukodystrophy, a genetic disorder of white matter of the central nervous system, mainly affecting young children (1). Patients with VWM display chronic neurological deterioration with additional episodes of rapid and severe decline provoked by stresses, especially febrile infections (1, 2). Neuropathology of post-mortem brain shows white matter rarefaction and cystic degeneration with feeble astrogliosis, profound lack of myelin, and immature astrocytes and oligodendrocytes (3) . There is no cure for VWM and patients die prematurely. Recessive mutations in any of the 5 genes encoding the subunits for eukaryotic translation factor 2B (eIF2B) cause VWM (4, 5) . Mutations reduce the activity of eIF2B (6) (7) (8) . eIF2B is conditional for mRNA translation initiation per se and essential for regulating protein synthesis rates and orchestrating the integrated stress response (ISR, Fig.1a ) (9) . VWM mouse models with homozygous (ho) missense mutations in eIF2Bδ (Arg484Trp) or eIF2Bε (Arg191His) subunits are representative of the human disease (2b4 ho and 2b5 ho mice) (10) . These mutations correspond to the eIF2Bδ Arg483Trp and eIF2Bε Arg195His mutation in patients. Each mutation reduces eIF2B activity in biochemical assays and causes a severe VWM phenotype (11, 12 , as reflected by earlier disease onset, more severe motor dysfunction, lower body weight, shorter life span, and severer brain pathology (10) . Using these mice, we showed that astrocytes are the primarily affected cell type (10) . Considering the housekeeping function of eIF2B in all cells, it is remarkable that a defect in eIF2B predominantly affects astrocytes. The underlying mechanism is unclear. We hypothesize that translation of specific mRNAs in brain is altered by eIF2B mutations, primarily impacting astrocytes. In this study we perform polysomal profiling to identify and quantify polysome-associated mRNAs and find differential expression of ATF4-regulated mRNAs in VWM mouse brain, indicative of enhanced expression of ATF4 and its transcriptome by reduced eIF2B activity. These changes are already seen at an early disease stage with minimal signs of white matter damage. The expression level of the ATF4-regulated transcriptome correlates positively with disease development and severity. Immunohistochemistry of VWM mouse brain reveals expression of ATF4 and its target 4EBP1 (13, 14) only in astrocytes. We use ISRIB, an ISR inhibitor (15) (16) (17) (18) in VWM mice to modulate the deregulated ISR and study the impact of this modulation on the disease. ISRIB stabilizes the eIF2B complex by direct binding (16, 19, 20) . As a consequence, ISRIB enhances eIF2B activity, which reduces the expression of ATF4 and impacts expression of the ATF4-regulated transcriptome (16, 18, 19) . The compound has been successful in treatment of a prion-infected mouse model for neurodegeneration (15) . We show that ISRIB normalizes ATF4 expression, astrocyte morphology, brain pathology and motor skills of VWM mice.
Results

Polysomal profiling reveals 33 mRNAs with altered translation in brains of 2b5 ho versus WT mice
We performed polysomal profiling with forebrains of 4-month-old wild-type (WT) and 2b5 ho mice, shortly before onset of clinical signs in 2b5 ho mice (10) . We reasoned that at this age eIF2Bε
Arg191His-regulated changes in mRNA translation would be detectable, while general changes in mRNA translation in response to tissue damage would be minimal. The polysomal profiles generated from WT and 2b5 ho samples were similar, showing that bulk mRNA translation was not grossly affected by the mutations (data not shown). The relative distribution between monosome and polysome fractions was determined for each mRNA per genotype. Differential distribution between the WT and 2b5 ho samples was found for 33 mRNAs (Suppl. Table 1 ); 23 mRNAs were shifted towards the polysome fraction and 10 towards the monosome fraction in 2b5 ho mouse forebrain samples,
indicative of altered translation rates in 2b5 ho brain. We evaluated the findings of the polysomal profiling for a number of candidates with qPCR. The majority of the mRNAs with altered translation rates accumulated at increased levels in monosome and polysome fractions from brain of 2b5 ho mice (Fig. 1b) . Apparently, these mRNAs are both transcriptionally and translationally regulated. Strikingly, 17 out of the 33 differentially translated mRNAs are regulated by transcription factor ATF4 ( Fig. 1a ) (13) .
Overrepresentation analysis of mRNAs with differential polysome association shows altered ATF4-driven transcription in 2b5 ho mouse and VWM patient brain
Most translationally regulated mRNAs were also regulated at the transcriptional level. We therefore performed the overrepresentation analysis with the eIF2Bε
Arg191His
-regulated polysome-associated mRNAs, without taking into account their distribution between the monosome and polysome fractions. We identified 176 mRNAs with an altered level of polysome association in forebrain of 2b5 ho compared to WT mice (115 up and 61 down, Suppl. File 2), indicating altered synthesis of the proteins they encode. We confirmed these findings with qPCR (Suppl. Fig. 1 ). Overrepresentation analysis (Fig. 2a) highlighted changes in amino acid transport, serine biosynthesis and glycine metabolism. Out of the 176 mRNAs 52 are regulated by ATF4 (13) , including Ddit3, the mRNA that encodes the transcription factor CHOP (Suppl. File 3). ATF4-regulated mRNA's were enriched 5-fold compared to the mRNAs, for which polysome-association was similar in WT and 2b5 ho forebrain (p<0.001; Suppl. File 3). We verified findings from mice in humans (Fig. 1d) ; expression of DDIT3, TRIB3 and EIF4EBP1 mRNA was increased in VWM patients' brain. Microarray analyses of total RNA from postmortem white matter tissue confirmed a 2-fold enrichment of ATF4-regulated mRNAs in differentially expressed mRNAs in VWM patients compared to controls (p<0.0001; Suppl. File 3).
Expression of the ATF4 transcriptome is accompanied by reduced eIF2α phosphorylation
We wondered whether the ATF4 transcriptome expression is enhanced in VWM brain due to ISR activation via eIF2α phosphorylation. In contrast with such hypothesis, we found that eIF2α phosphorylation in brain was significantly reduced in VWM compared to WT mice (Fig. 1c) . Dephosphorylation of eIF2α is mediated by protein phosphatase 1, using either CREP1 or GADD34 as co-factor(21). GADD34 expression is induced upon stress in an ATF4-and CHOP-dependent manner; GADD34 is essential for the negative feedback of the ISR and restores protein synthesis (Fig. 1a) , while CREP1 functions as a co-factor also in unstressed cells. Crep1 mRNA expression was similar, but Gadd34 mRNA expression was increased in 2b5 ho brain compared to WT brain (Fig. 1c ), in line with its to visualize the mRNA distribution in monosome fraction (A), polysome fractions (B1, less than 5 ribosomes per mRNA; B2, 5 or more ribosomes per mRNA). Graphs show average ± sd, n=3 (Akt, qPCR reference). Statistical significance was determined by two-way ANOVA with Sidak's correction; *p<0.05, **p<0.01, ****p<0.0001). (c) eIF2α phosphorylation, Gadd34 and Crep1 mRNA expression levels were measured in cerebellar tissue from WT and VWM mice, as indicated. Graphs show average ± sd, n=3 for eIF2α phosphorylation and n=6 for mRNA expression (Gapdh+Akt, qPCR reference). Statistical differences in eIF2α phosphorylation were determined using a one-way ANOVA followed by a Dunnet's correction. Differences between WT and 2b5 ho qPCR data were assessed with student T-test, *p<0.05, **p<0.01. (d) DDIT3, TRIB3, EIF4EBP1 mRNA levels, eIF2α phosphorylation, GADD34 and CREP1 mRNA levels were quantified in postmortem frontal white matter tissue from VWM patients and controls (negative controls without brain pathology, C1, C2 and disease controls CAR and MS; CAR, CARASAL; MS, multiple sclerosis). Expression differences among VWM patients inversely correlate with postmortem delay time (AKT+GAPDH, qPCR reference, n=1). Details on control and patients' tissue are listed in Supplementary File 4.
regulation by ATF4 and CHOP (22) (Fig. 1a) . In VWM patients' white matter tissue eIF2α phosphorylation was significantly decreased as compared to control tissue (Fig. 1d) . In line with this observation, GADD34 but not CREP1 mRNA levels were increased in VWM patient brain tissue compared to control tissue. The decreased level of eIF2α phosphorylation can be directly explained by increased expression of GADD34. The ISR constitutes part of the unfolded protein response (UPR), which is activated by endoplasmic reticulum (ER) stress (Fig. 1a) . UPR activation in patients' white matter was previously reported (23, 24). Therefore, we investigated activation of UPR branches regulated by ATF6 or IRE1α in 2b5 ho mouse brain. We measured specific markers for ATF6-driven transcription (Pdia4 mRNA) and IRE1α activation (Xbp1 mRNA splicing) (Suppl. Fig. 2 ) (25) (26) (27) . qPCR analyses did not show increased expression of the Pdia4 mRNA nor Xbp1 mRNA splicing, arguing against recent or ongoing activation of the UPR in 2b5 ho brain. The previously reported expression of UPR markers in patient brains was determined in end-stage disease (23, 24, 28) and could be related to that stage. We measured Pdia4 mRNA expression and Xbp1 mRNA splicing in mouse brain at the humane end point. Still, we did not observe an increased expression of the UPR markers compared to the WT brain (Suppl. Fig. 2 ). We further verified findings in human tissue and found comparable expression of PDIA3 and XBP1 splicing in white matter tissue from controls and VWM patients (Suppl. Fig. 2 ). Microarray analyses of total RNA from postmortem white matter tissue did not show enrichment of ATF6-and/or XBP1-regulated mRNAs either in differentially expressed mRNAs in VWM patients compared to controls (p=0.4507; Suppl. File 3). This indicates that eIF2B mutation does not chronically activate ER stress.
Expression of the ATF4 transcriptome in 2b5 ho mouse brain correlates with disease development and severity
We assessed expression levels for several mRNA candidates in mouse brain at ages ranging from postnatal day 0 (P0) to the humane end point (Fig. 2b) . From P0 to P14 none of the tested candidates differ in expression level between WT and 2b5 ho brain. From P28 onwards the expression of ATF4-regulated mRNAs changed progressively in 2b5 ho but not in WT brain (Fig. 2b) . The maximal expression differences were measured at the humane end point. We also measured the expression of several ATF4-regulated mRNAs in brains of 2b4 ho , 2b5 ho and 2b4 he 2b5 ho mice, displaying a severity range from mild to severe (Fig. 2b) Graphs show average ± sd, n=2. Statistical analysis on the differences at groups of different ages was done for each mRNA using a two-way ANOVA (genotype*day interaction all days) followed by 2 two-way ANOVAs for each mRNA (one comparing data of <P21 with ≥P21 and one comparing data of <P28 with ≥P28 for genotype*day interaction) using SPSS. Cerebella of indicated mouse genotypes were analyzed at 4-month-old age (Gapdh+Akt, qPCR reference). Graphs show average ± sd, n=3 (n=4 for 2b4 ho ). Statistical differences were determined using a one-way ANOVA followed by Tukey's correction. **p<0.01, ***P<0.001, ****p<0.0001.
ATF4 and 4E-BP1 expression in white and gray matter astrocytes
To investigate which specific cells or brain areas display an activated ATF4 transcriptome we performed immunohistochemistry (IHC) for ATF4 as well as 4E-BP1 on WT and VWM mouse brain (Fig. 3) . The tested antibodies for CHOP, TRIB3 and SLC3A2 did not yield specific signals and were not used. IHC for ATF4 on WT and 2b5 ho brain showed nuclear ATF4 immunoreactivity in cerebellum, corpus callosum and cortex in 2b5 ho brain only ( Fig. 4 ). Doublestainings with antibodies against Olig2 and ATF4 to investigate if ATF4 is expressed in oligodendrocytes are technically challenging. The Olig2 signal is much higher than the ATF4 signal and both signals localize in the nuclei, potentially causing false-negative findings.
Immunofluorescence would overcome this problem, but ATF4 was not detected in this type of assay in our hands. Co-stainings for Olig2 and 4E-BP1 were thus favored, as the signal for 4E-BP1 localizes to the cytoplasm and not to the nucleus. 4E-BP1-positive cells with the morphology of astrocytes were also detected in the frontal white matter, cerebellum, and cortex of post-mortem brain tissue from VWM patients (Fig. 3 ). 4E-BP1-positive cells with the morphology of oligodendrocytes or neurons were not observed in VWM patient brain tissue. 4E-BP1-positive astrocytes, oligodendrocytes or neurons were not observed in brains from MS or CARASAL patients (data not shown). Staining with the ATF4 antibody did not give a specific signal in human brain and prevented determination of the localization of ATF4 protein in human VWM brain sections. 
ISRIB injections differentially normalize clinical signs of VWM mice
We postulate that expression of the ATF4 transcriptome in astrocytes underlies their dysfunction. We targeted the ISR with the ISR inhibitor ISRIB (15) (16) (17) (18) 33) to reduce the expression of the ATF4 transcriptome. We developed a vehicle to overcome ISRIB's insolubility, which hinders bio-availability in mice (15 
ISRIB impacts expression of ISR mRNA markers and improves histopathology
Expression of several ATF4-regulated mRNAs was measured in cerebella, collected from placebo-and ISRIB-injected mice at the end of the experiment. ISRIB reduced expression of Atf4 and ATF4-regulated mRNAs in the VWM mice and most consistently in 2b4 ho 2b5 he mice (Fig. 5a ). ISRIB did not affect the phosphorylation of eIF2α in 2b5 ho and 2b4 ho 2b5 he mice, despite reduced Gadd34 mRNA levels (Fig. 5a ). ISRIB reduced expression of the Eif4ebp1 mRNA and 4E-BP1 protein in ISRIB-injected 2b4 ho 2b5 he mice (Fig. 5a) , which was not observed in ISRIB-injected WT or 2b5 ho animals.
Bergmann glia morphology in VWM mouse brain was improved by ISRIB, as visualized by GFAP (not shown) and S100 IHC, more clearly in 2b4 ho 2b5 he than in 2b5 ho mice (Fig. 5b) . Although ISRIB treatment tended to also improve Bergmann glia localization, in quantification the changes in proportion of mislocalized Bergmann glia did not reach significance (Fig. 5c ). Bergmann glia are localized closer to the Purkinje cells with ISRIB treatment, but have not reached or maintained their normal position completely (Fig. 5b) . The number of nestin and GFAP double-positive immature astrocytes normalized in ISRIB-injected 2b4 ho 2b5 he mice and was reduced in 2b5 ho mice, although statistical significance was not reached for the latter genotype (Fig. 5d, e) . ISRIB effects on myelin in VWM mice were evident in mature myelin MBP and MOG mRNA levels and MOG IHC only in 2b4 ho 2b5 he mice (Fig. 5f, g ). No ISRIB effects on histology were observed in WT mice (data not shown).
The differential effect of ISRIB on body weight, clinical signs, expression of the ATF4-regulated transcriptome and histopathology in 2b5 ho mice versus 2b4 ho 2b5 he mice is striking (Fig. 4 and 5 ). ISRIB concentrations in venous blood samples drawn after 2 weeks of injections were similar in 2b5 ho and 2b4 ho 2b5 he mice, albeit lower than in WT mice (Suppl. Fig. 6a ). ISRIB's concentrations in post-mortem blood and brain samples were similar in all three genotypes (Suppl. Fig. 6b ), indicating that ISRIB's differential effect on phenotypic measures cannot be attributed to differences in ISRIB bioavailability in brain. ISRIB's therapeutic effect may be influenced by the identity of the mutation. A recent study shows that ISRIB's efficacy is increased by the Arg483Trp mutation in human eIF2Bδ (19) . We thus measured ISRIB's effect on protein synthesis rates in cultured astrocytes from WT, 2b5 ho and 2b4 ho 2b5 he mice undergoing a UPR (Suppl. Fig. 6c ). ISRIB was more effective in 2b4 ho 2b5 he astrocytes than in WT and 2b5 ho astrocytes, although statistical significance was not reached (Suppl. Fig. 6c ). In parallel, we determined ISRIB's effect on protein synthesis in transfected astrocytes and found that protein synthesis in 2b4 ho 2b5 he astrocytes was more sensitive to low concentrations of ISRIB than WT astrocytes (Suppl. Fig. 6d ). Increased ISRIB sensitivity was not observed in 2b5 ho astrocytes (Suppl. 
Discussion
VWM is a devastating leukodystrophy characterized by disappearance of cerebral white matter (1). In 2001, it was found that the basic VWM defect concerns eIF2B, which is pivotal in initiating translation and regulating its rate, especially under ISR activating conditions (4, 12, 34, 35) . The housekeeping function of eIF2B is in stark contrast with its selective brain white matter involvement. Until now, the pathomechanisms of VWM have remained unclear. Available evidence indicates primary astrocyte involvement, secondary impediment of oligodendrocyte maturation and function, and negligible neuronal involvement (3, 10, 36, 37) . In this study we aim at unraveling VWM pathophysiology. Using polysomal profiling to reveal mRNAs that are differentially translated in brains of 2b5 ho compared to mice, we demonstrate increased expression of an ATF4-regulated transcriptome in 2b5 ho brain from an early age, before disease onset. Its expression level correlates with disease development and severity. Strikingly, this ATF4-regulated transcriptome is expressed selectively in astrocytes. To conclude, astrocytes, and no other cells, in VWM brain constitutively express an ATF4-regulated transcriptome. We show that this astrocyte-selective expression is specific for VWM and is not a general response to neurodegeneration. Previously, activation of the UPR was hypothesized in VWM, presumably through a feedback response sensitizing the ER to stress (23). Our current study disproves this concept. Differential expression of UPR-regulated mRNAs was not detected in VWM patients. The reduced levels of phosphorylated eIF2α in brains of 2b5 ho mice and VWM patients argues against cell stress and UPR activation as initiating cause for the enhanced ATF4 transcriptome in VWM astrocytes. Reduced activity of mutant eIF2B (12) by itself explains the increased expression of ATF4 and its transcriptome, including the mRNA encoding GADD34. Increased GADD34 explains the decreased phosphorylated eIF2α levels. Reduced eIF2α phosphorylation probably compensates, albeit partially, the reduced activity of the mutant eIF2B. If the compensation had been sufficient, ATF4 levels would have been similar in WT and mutant brain tissue. We furthermore indicate that the ATF4-regulated transcriptome is an essential part of VWM pathomechanisms. We previously demonstrated that guanabenz improves white matter and astrocyte pathology in 2b5 ho mice (38) . Guanabenz is an α2-adrenergic receptor agonist that also targets the ISR and reduces expression of the ATF4-regulated transcriptome (39) . We now demonstrate that ISRIB, which activates eIF2B, reduces the expression of the ATF4-regulated transcriptome, improves VWM astrocyte and white matter pathology and ameliorates the clinical disease in VWM mice. Surprisingly, ISRIB did not affect eIF2 phosphorylation in VWM mice in our experiment. An increase in eIF2 phosphorylation would have been expected, as ISRIB reduced Gadd34 mRNA levels in VWM mice. Possibly, the ISRIB-induced reduction in GADD34 protein level was not sufficient to achieve this. The ATF4 expression was not completely normalized by ISRIB in either VWM genotype, as exemplified by 4E-BP1 protein expression that was still detected in their brain tissue (Fig. 5 ). Both findings suggest that ISRIB treatment does not fully normalize the eIF2B activity, but leads to a better compensated system that still in part depends on reduced eIF2 phosphorylation. We conclude that reduced activity of mutant eIF2B initiates the disease in VWM. It activates the enhanced expression of ATF4 and the ATF4-regulated transcriptome, which is moderated through the GADD34 feedback loop, decreasing eIF2α phosphorylation, albeit insufficiently to normalize eIF2B activity and prevent the disease. ISRIB targets eIF2B directly and stabilizes eIF2B complex formation through an interaction with the eIF2Bδ:eIF2Bβ interface (20, 40, 41) . Its effect may thus be dependent on the specific mutation. The eIF2Bδ Arg483Trp mutation interferes with eIF2B complex stability (12) , whereas the eIF2Bε Arg195His mutation does not and possibly reduces eIF2B activity through another mechanism (42).
Our results indicate that ISRIB probably preferentially impacts eIF2B with complex-destabilizing mutations.
The question how ISR deregulation causes pathology remains difficult to answer. Our overrepresentation analyses on the regulated mRNAs in brain of 2b5 ho mice highlight increased functions of amino acid transport and biosynthesis of serine, glycine and cysteine. Several of these genes are regulated by ATF4 (13, 39) . Increased serine and glycine levels have been reported in cerebrospinal fluid in VWM patients (43) , indicating that these processes are indeed deregulated. Interestingly, serine, glycine and cysteine are used with glutamate for glutathione (GSH) synthesis (44) . The ATF4-regulated transcription is known to aid in counteracting tissue damaging reactive oxygen species (ROS) (45) . ROS is one of the stressors increasing the level of eIF2α phosphorylation (46, 47) , but in brains of VWM mice and VWM patients, eIF2α phosphorylation is low, suggesting that ROS levels are not abnormally enhanced in VWM brain. Thus, the increased synthesis of the antioxidant GSH in astrocytes may induce reductive shifts in the steady-state redox potential of the VWM brain (44, 48, 49) . Especially in astrocytes a reductive shift may interfere with proliferation and maturation of oligodendrocyte precursor cells (50) (51) (52) . Strikingly, an astrocyte-dependent impairment of oligodendrocyte maturation is a central feature of VWM (3, 10, 36, 53) . The impact of astrocytic redox imbalance may be higher on oligodendrocytes than on neurons, which intrinsically have extremely high levels of glutathione (54), explaining the sparing of this cell type. All data combined suggest that the defect in oligodendrocyte maturation may be due to a reductive shift in redox potential in mutant astrocytes effectuated by the expression of ATF4 (Fig. 6) .
Concluding remarks
This study shows that an ISR deregulation selectively occurs in brain astrocytes of VWM mice and VWM patients. Effects of ISR modulation demonstrate that its derangement is a pivotal part of VWM pathogenesis. ISRIB reduces the expression of ATF4-regulated transcriptome, improving disease outcome in VWM mouse models. The study reveals that the ISR is a viable drug target for treating VWM. . The ATF4-regulated transcriptome in VWM astrocytes affects amino acid metabolism, serine biosynthesis and glycine metabolic processes resulting in increased levels of the reducing compound glutathione (GSH). GSSG:GSH indicates redox potential (oxidized:reduced glutathione), with capitalized font indicating the most abundant type of glutathione (GSH, reduced; GSSG, oxidized). GSH may induce a reductive shift in redox potential interfering with maturation of oligodendrocyte precursors (OPC) to mature oligodendrocytes. The resulting reductive change in redox status could inhibit oligodendrocyte maturation, a process known to be driven by oxidative shifts in redox potential. Increased levels of serine and glycine (indicated with green arrows) have been described in cerebrospinal fluid from VWM patients. ISRIB impacts eIF2B activity and reduces ATF4 expression, consequently expecting to influence redox potential and improve OPC maturation.
Methods
Animal models
The mouse strains with a homozygous point mutation in the eIF2Bε (Eif2b5 Arg191His/Arg191His , 2b5 ho ) or eIF2Bδ subunit (Eif2b4
, 2b4 ho ) are described elsewhere (10) . Crossbreeding of the two mutant lines generated mice that are homozygous for the eIF2Bδ Arg484Trp mutation and heterozygous for the eIF2Bε R191H mutation (2b4 ho 2b5 he ) or heterozygous for the eIF2Bδ Arg484Trp mutation and homozygous for the eIF2Bε R191H mutation (2b4 he 2b5 ho ). Mice were weaned at P21
and kept with a 12 hour light/dark cycle with food and water provided ad libitum. The animals were sacrificed at different ages depending on the experiment. When the mutant mice became so ataxic that they could not reach the food on top of the cages, food was placed inside the cages and eventually replaced by suspensions of water and ground food pellets. The humane end point (HEP) for the mutant mice was defined by weight loss of more than 15% of body weight for 2 consecutive days and severe ataxia.
Study approval
All animal experiments were carried out in compliance with the Dutch and European law and with approval of the local animal care and use committee of the VU University [license FGA 11-05A5].
Written informed consent was provided by patients or their parents for the collection and use of patients' samples. The Medical Ethics Committee of the VU University Medical Center approved of the procedures.
Sample preparation
Mice were sacrificed by cervical dislocation at indicated ages. The individual organs were snap-frozen in liquid nitrogen immediately after they were taken out. Brains were divided in four parts: 1) olfactory bulb (which was discarded and not investigated), 2) forebrain including cortex and corpus callosum, 3) cerebellum and 4) the remaining structures, including striatum and hippocampi. All organs were stored in a -80°C freezer until further use, except for obtaining nuclear lysates which were prepared from fresh tissue. Cytoplasmic lysates of mouse organs were prepared by grinding each organ with pestle and mortar under liquid nitrogen. All chemicals were purchased from Sigma-Aldrich unless otherwise stated. The frozen powder was resuspended with a minimixer in 600 μl lysis buffer, composed of 20 mM Tris pH 7.4, 100 mM potassium acetate, 3 mM magnesium acetate, 3 mM dithiothreitol, 0.5% Triton-X100, 0.5% sodium deoxycholate and protease inhibitors (Roche). Samples were kept on ice for 15 min and triturated three times with a 23G needle. The samples were centrifuged for 10 min at 4 °C to remove nuclei, membranes and debris. Samples were aliquoted and stored at -80 °C or applied to sucrose gradients for fractionation into polysomes and monosomes.
Polysomal profiling
Equal volumes of cytoplasmic lysate were loaded onto a 15%-50% isokinetic sucrose gradient (containing 1 ug/ml cycloheximide, 100 ug/ml heparin, and 7 mM β-mercaptoethanol) and centrifuged for 45 min at 4°C in a Beckman SW55 ultracentrifuge at 52.000 rpm. The gradient was fractionated into polysome fractions (middle (B1) and bottom (B2)) and a monosome fraction (top (A) fraction). The gradients were pushed upwards by a 70% glycerol solution through an Uvicord with a velocity of 1 ml per min. mRNA was isolated from the fractions using Trizol TM reagent (Invitrogen), after addition of 300 mM sodium acetate and 20 mM EDTA. After mixing by inverting the tube, the solutions were frozen for at least 20 min at -80 °C. After thawing chloroform was added and the sample was centrifuged for 10 min at 4000 rpm (4 °C; Eppendorf). The aqueous phase was isopropanol-precipitated on ice in the presence of linear acrylamide (20 µg/ml; Invitrogen). The pellet was air-dried for approximately 1 min and resuspended in non-DEPC-treated nuclease-free water (Ambion). Total RNA was precipitated with LiCl (4 M final concentration) at -20 °C for at least one hour. Samples were centrifuged at maximum speed (Eppendorf) for at least one hour at 4 °C. The pellet was washed with ice-cold 70% EtOH, resuspended in 20 μl non-DEPC-treated nuclease-free water (Ambion). An additional ethanol precipitation was performed if the A230/A260 ratio of the RNA was suboptimal (measured by (NanoDrop 2000C, ThermoFisher). mRNA was subjected to Cy3 and Cy5 labeling and labeled cRNA was applied to expression microarray analyses at the local microarray facility using Agilent 4x44K Mus musculus dual channel array slides, each consisting of 4 arrays with 44,000 2-channel probe spots (Cy3 and Cy5).
Data processing and variance analysis
Expression data were obtained from two independently conducted microarray experiments, each using two mice per genotype. In the first experiment the gradient was fractionated into one polysome (B) and one monosome fraction (A) and in the second experiment into two polysome fractions (B1, B2) and one monosome fraction (A). The signals for mRNAs in B1 and B2 fractions were averaged. Parsing and normalization of the microarray data was done in R using the Limma package (55) . Normalization was done in two steps, firstly within-array normalization was applied in the form of Loess normalization without background subtraction. Secondly, between-array normalization was applied using quantile normalization. Variance was evinced through estimation of within-block correlation using the intraspotCorrelation function and subsequently by fitting linear models to all probe log-intensities, using the lmscFit function (56) . Two different kinds of variance were estimated, firstly the variance in mRNA abundance between WT and 2b5 ho was assessed and secondly the variance in the polysome densities of each mRNA between WT and 2b5 ho was calculated. The former was done by taking the difference of 2 log-transformed expression values: Δ(Δ(B 2b5ho ,A 2b5ho ),Δ(B wt ,A wt )) and Δ(B 2b5ho ,B wt ), in which B refers to polysome fraction and A to monosome fraction. These tests are referred to as ΔΔBA and ΔB respectively. For all tests a false discovery rate (FDR) cut-off of 0.05 was calculated according to the Benjamini-Hochberg method (57) to select probes that show reliable variance.
Overrepresentation analysis
A threshold was set for what constitutes gene expression in the resulting dataset. The probe average intensity was plotted against its frequency, showing a bimodal distribution of expressed and nonexpressed genes. The probe intensities were plotted against the false discovery rate (FDR) to determine the threshold between expression and non-expression. The intensity for which FDR was smaller than 0.05 was 6.29; this intensity was taken as the cut-off value for what constitutes expression. Using this cut-off a denominator list was generated, representing WT mouse brain tissue expression. This list consists of 22,473 probe sets, out of a total of 43,379. Next, we generated a list of probe sets that are differentially associated with polysomes from WT versus 2b5 ho brain (ΔB).
Overrepresentation analysis was performed with the software program Go-Elite version 1.2.5 (58) . In short, the list of regulated mRNAs (ΔB) in 2b5 ho mouse brain was investigated for pathway, ontology or gene set. The number of permutations was kept at the default value of 2000. Only results being non-redundant with a Z-score> 2, a p-value< 0.05, a FDR<0.2 and fold change of > 1 or <-1 were selected.
To investigate enrichment of ATF4-regulated mRNAs we compared published data sets of ATF4-dependent mRNAs (Suppl. Table S4 in (13)) with the denominator list as well as the differentially polysome-associated mRNAs (ΔB). Significant differences were determined using a Fisher exactsquare test. A similar approach was undertaken for a microarray analyses on total RNA samples from postmortem human white matter tissues (6 controls, 6 VWM patients, details listed in Supplementary Data File 4). A table of homologous genes of mouse and human was downloaded on January 16, 2018 from the Mouse Genome Database (MGD) (59) . The "Symbol" column in this table was used to match human genes from the microarrays of this study with the mouse genes from the published study (13) . Enrichment was subsequently determined by comparing the same published data set of ATF4-dependent mRNAs with the denominator list (cut-off determined as 6) and the differentially accumulated mRNAs (FDR<0.05). In parallel from the same publication we distilled ATF6-and IRE1αa-regulated mRNAs by subtracting ATF4-regulated mRNAs from the UPR-regulated mRNAs in response to tunicamycin (Suppl. Table S4 (13)). This non-ATF4 list was then compared with the denominator list (cut-off determined as 6) and the differentially accumulated mRNAs (FDR<0.05) in VWM white matter. Significant differences were determined using a Fisher exact-square test.
Quantitative PCR (qPCR)
Total RNA was extracted from mouse brain and human white matter with Trizol TM reagent (Invitrogen). Reverse transcription and qPCR were performed as described previously (60) . Primers were designed using PerlPrimer v1.1.1928 or PrimerBLAST. Depending on the experiment Akt, Gapdh or Akt + Gapdh mRNA was used as reference as indicated in figure legends. The primers used in this study are listed in Suppl. File 1.
Western blotting
Total protein concentration in cytoplasmic was measured by Bradford according to the manufacturer's instructions. Equal amounts of protein were applied to SDS-PAGE. In-gel protein loading and sample transfer was checked with 2,2,2-trichloroethanol as described (61) . Membranes were blocked with 5% non-fat-dry-milk and incubated with one of the following primary antibodies (anti-eIF2α, SC-11386/SantaCruz or anti-4E-BP1, 53H11/Cell Signaling, or anti-ATF4 D4B8/Cell Signaling). Membranes used for detecting phosphorylated eIF2α were blocked with 5% bovine serum and incubated with anti-Ser51-phosphorylated eIF2α antibody (Cell Signaling, D9G8). After incubating with secondary antibody (HRP-labeled anti-IgG rabbit, 1:10000, Dako, P0448), the signal was detected with an enhanced chemiluminescent substrate (SuperSignal West Femto Substrate, Fisher Scientific) and imaged with Image Studio on the LI-COR Odyssey Fc Imager (60) .
Immunohistochemistry
Immunohistochemistry (IHC) and immunofluorescence (IF) was performed as described (10) . IHC and IF were performed with antibodies against ATF4 (#11815, 1:50, Cell Signaling), 4EBP1 (#9644, 1:500, Cell Signaling), GFAP (Z0334, 1:1000, DAKO), Olig2 (AB9610, 1:200, Millipore), S100β (S2532, 1:1000, Sigma), nestin (#611658, 1:200, BD Bioscience). Briefly, brains were perfusion-fixed with 4% paraformaldehyde (PFA) and embedded in paraffin. Paraffin-embedded tissue sections (6-μm-thick) were deparaffinized and endogenous peroxidases where blocked with 0.3% H 2 O 2 . After heat-induced antigen retrieval in 0.01 M citrate buffer (pH 6) or 10 mM Tris, 1 mM EDTA buffer (pH 9), sections were blocked with 5% normal goat serum (Thermofisher Scientific) for S100β this blocking step was replaced by a Mouse on Mouse (M.O.M.™) blocking reagent (Vector laboratories). For ATF4 detection, tissue was permeabilized with 0.1% saponin and 0.5% Triton X100. Immunoreactivity was detected with DAB chromogen (DAB+, DAKO). For double stainings, tissue was incubated with primary antibody and developed with 3,3'-diaminobenzidine DAB as described above. After a second heat-induced antigen retrieval step, incubation of the second primary ab was performed. Immunoreactivity was detected with liquid permanent red (LPR) substrate chromogen (DAKO).
Images were taken with a Leica DM6000B microscope (Leica Microsystems). Numbers of nestinpositive astrocytes were determined by immunofluorescence as described (10) . The ratio of mislocalized:normal Bergmann glia was determined basically as described(10) with minor changes: secondary antibodies against anti-IgG were labelled with 488 (S100β) rather than HRP and counterstained with 0.1% Sudan Black. Images were obtained with a Leica 5000b fluorescent microscope. DAPI was included in mounting media to stain for nuclei. only (placebo) to investigate side-effects caused by the daily injection procedure and constituents of the vehicle. Group sizes were n=6 for WT mice and n=14 for VWM mice (n=68 in total). Injections were placed on either left hand or right hand side of the abdominal wall at alternating days. Body weight was measured daily and blood samples were taken by submandibular vein bleed after two weeks of daily injections. ISRIB concentrations were determined in venous blood two weeks after start of the injections and in post-mortem blood and brain as previously described (15) with some minor modifications.
ISRIB trial
2 H 10 -ISRIB (synthesized by Herman ten Brink, Amsterdam UMC, location VUmc) was added to the samples for precise quantification. The samples were reconstituted in acetonitrile and separation of ISRIB was achieved on a Waters Acquity UPLC BEHC18 1.7µm 2.1x100mm column and quantitative analysis was performed by LC-MS/MS by using an API 5000 (AB Sciex) mass spectrometer in positive electrospray ionization mode with MRM m/z 451-266 and m/z 461-276 for ISRIB and 2 H 10 -ISRIB respectively.
Motor skills (neuroscores, Balance Beam) were assessed at indicated time points as previously described (10, 62) . Mice were subjected to a catwalk set-up for a quantitative gait analysis, using CatWalk XT 10.6 (Noldus Information Technology, Sylics) prior to being euthanized. The machine consists of an enclosed glass walkaway (width), illuminated from the distal long edge with a green light and from the ceiling with a red light. Mice are placed onto the glass plate and as the animals' paws get in contact with the glass floor, the light is internally reflected, captured by a high-speed video camera and transformed in a digital image. Images were analysed by using the automated footprint classification provided in the CatWalk XT 10.6 software with a minimal of consecutive steps of six, average speed ranging from 20.0 to 60.0 cm/second and a maximum allowed speed variation of 40%. All CatWalk data has been analysed by the same researcher in order to reduce interrater variabilities and further processed by a different researcher, blinded to treatment and genotype (63) . At the end of the experiment animals were euthanized by cervical dislocation or perfusion-fixation with 4% PFA. Brains were taken out for molecular and neuropathological examination.
Protein synthesis measurements
Protein synthesis rates were measured in adult mouse astrocytes with AHA-incorporation and statistical analysis of the data was performed as previously described (64) . Primary cultures of adult mouse astrocytes were transfected with pGL3-Gapdh and pNL1.1-Atf4 as described (64) . Cells were exposed to 300 nM thapsigargin for 16 hours in absence or presence of increasing concentrations of ISRIB. Luciferase activity was measured as before. The pNL1.1-Atf4 construct comprises the murine Atf4 promoter from nucleotide -1600 to +1023 with respect to the transcription start site (the intron 1 sequence is not present in the construct). The construct was made as described (64) using infusionforward primer (5'-TGGCCTAACTGGCCGCACTGGCTGTTTGGAGAC) and infusionreverse primer (3'-AGTGTGAAGACCATGTTGTGGGGCTTTGCTGGA). The construct was not responsive to thapsigargin treatment nor ISRIB and therefore the pNL1.1-Atf4-derived luciferase activity was not included in the manuscript.
Statistical analysis
For the validation of polysome association using qPCR, statistical differences were determined using a two-way ANOVA (genotype and fraction type as factors) followed by a Sidak's multiple comparison test, according to GraphPad Prism software. Comparisons between WT and 2b5 ho samples were analyzed with Student's t-test using GraphPad
Prism software. For qPCR and Western blot analysis between more than two genotypes, statistical differences were determined using a one-way ANOVA followed by a Tukey's multiple comparison test, using GraphPad Prism software. Differences were interpreted as significant when p<0.05. Statistical analysis on the differences at groups of different ages was done for each mRNA using a two-way ANOVA (genotype*day interaction all days) followed by 2 two-way ANOVAs for each mRNA (one comparing data of <P21 with ≥P21 and one comparing data of <P28 with ≥P28 for genotype*day interaction) using SPSS; p<0.01 was considered significant. 
